Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Ltd experienced a pronounced decline on 5 Dec 2025, with the stock registering a sharp fall of 4.99% in a session dominated exclusively by sell orders. This extreme selling pressure, coupled with the absence of buyers, signals distress selling and highlights the challenges facing the company within the Pharmaceuticals & Biotechnology sector.

Sotac Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market assessment, reflecting shifts across key evaluation parameters. This development comes amid a backdrop of steady stock returns and a complex financial profile, prompting investors to reassess the company’s position within its sector.

Sotac Pharmaceuticals Ltd witnessed a significant surge in its share price on 20 Nov 2025, hitting the upper circuit limit of 5.0% to close at ₹131.25. This movement reflects robust buying interest and a notable outperformance relative to its sector and benchmark indices, signalling heightened investor enthusiasm in the Pharmaceuticals & Biotechnology space.

Sotac Pharmaceuticals Ltd faced notable trading activity as its stock reached the lower circuit limit, closing at Rs 122.55. The stock's performance lagged behind the sector, with a total traded volume of 0.024 lakh shares. Its positioning relative to moving averages indicates volatility typical of microcap stocks.

Sotac Pharmaceuticals Ltd is experiencing notable selling pressure, marked by consecutive losses and a significant decline in its stock performance. Over the past month and year, the company has underperformed compared to the Sensex, raising concerns about its longer-term trajectory despite a positive year-to-date performance.

Sotac Pharmaceuticals Ltd experienced notable trading activity as its stock hit the lower circuit limit, closing at Rs 118.75. The stock's performance lagged behind the sector, with a significant increase in investor participation. It remains above its short-term moving averages but below longer-term ones, indicating mixed trends.

Sotac Pharmaceuticals Ltd is experiencing notable selling pressure, with the stock showing only sellers today. The company has faced consecutive losses, reflecting a challenging market environment. Despite a slight weekly gain, its monthly and quarterly performances have been negative, indicating potential weakening trends amid broader market dynamics.

Sotac Pharmaceuticals Ltd is experiencing significant selling pressure, marked by consecutive losses and underperformance compared to the Sensex. The stock has declined over various time frames, including a notable drop over the past year, while remaining above some short-term moving averages but below longer-term ones.

Sotac Pharmaceuticals Ltd experienced notable trading activity as its stock hit the lower circuit limit, closing at Rs 118.75. The stock's performance lagged behind the sector, with a total volume of 0.012 lakh shares traded. Investor participation increased, with delivery volume rising by 25% compared to the previous average.

Sotac Pharmaceuticals Ltd has shown notable activity today, reaching its upper circuit limit with a high price of 125.1. The stock's trading volume and turnover indicate sufficient liquidity, while its performance surpasses both sector averages and broader market indices, reflecting a strong position within the pharmaceuticals industry.

Sotac Pharmaceuticals Ltd has gained attention by reaching its upper circuit limit, with a notable increase in stock price. The trading session saw a total volume of 0.012 lakh shares and a turnover of approximately Rs 0.01362 crore. Despite reduced investor participation, the stock showed resilience in the market.

Sotac Pharmaceuticals Ltd is experiencing notable buying activity, with a 5.00% increase today, outperforming the Sensex. Despite recent gains, the stock has faced longer-term challenges, showing declines over the past month and three months, while year-to-date performance remains modest compared to the broader market.